Shares in the American biotechnology group hit fresh highs after it published data that suggested the efficacy of its jab compared favourably with that of a rival. Moderna’s six-month efficacy fell only marginally from a previous trial that put it at 94 per cent. In contrast, Pfizer and BioNTech said last week that their vaccine’s efficacy slipped to about 84 per cent six months after a second dose. SponsoredBased in Cambridge, Massachusetts, Moderna was founded in 2010. Its market value stands at $174 billion after its shares almost

Source: The Times August 05, 2021 23:03 UTC